|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM25 |
Gene summary for TMEM25 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM25 | Gene ID | 84866 |
| Gene name | transmembrane protein 25 | |
| Gene Alias | TMEM25 | |
| Cytomap | 11q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q86YD3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84866 | TMEM25 | LZE4T | Human | Esophagus | ESCC | 2.32e-04 | 1.37e-01 | 0.0811 |
| 84866 | TMEM25 | LZE22T | Human | Esophagus | ESCC | 2.36e-07 | 6.38e-01 | 0.068 |
| 84866 | TMEM25 | LZE24T | Human | Esophagus | ESCC | 2.44e-11 | 3.13e-01 | 0.0596 |
| 84866 | TMEM25 | P2T-E | Human | Esophagus | ESCC | 7.77e-17 | 2.35e-01 | 0.1177 |
| 84866 | TMEM25 | P4T-E | Human | Esophagus | ESCC | 9.35e-18 | 4.19e-01 | 0.1323 |
| 84866 | TMEM25 | P5T-E | Human | Esophagus | ESCC | 4.68e-11 | 1.77e-01 | 0.1327 |
| 84866 | TMEM25 | P8T-E | Human | Esophagus | ESCC | 1.55e-10 | 2.36e-01 | 0.0889 |
| 84866 | TMEM25 | P9T-E | Human | Esophagus | ESCC | 1.27e-07 | 1.27e-01 | 0.1131 |
| 84866 | TMEM25 | P10T-E | Human | Esophagus | ESCC | 2.46e-17 | 3.60e-01 | 0.116 |
| 84866 | TMEM25 | P11T-E | Human | Esophagus | ESCC | 1.87e-15 | 6.49e-01 | 0.1426 |
| 84866 | TMEM25 | P12T-E | Human | Esophagus | ESCC | 5.62e-30 | 4.52e-01 | 0.1122 |
| 84866 | TMEM25 | P15T-E | Human | Esophagus | ESCC | 3.44e-04 | 1.22e-01 | 0.1149 |
| 84866 | TMEM25 | P16T-E | Human | Esophagus | ESCC | 3.65e-28 | 5.04e-01 | 0.1153 |
| 84866 | TMEM25 | P17T-E | Human | Esophagus | ESCC | 1.47e-03 | 2.64e-01 | 0.1278 |
| 84866 | TMEM25 | P21T-E | Human | Esophagus | ESCC | 1.47e-34 | 6.55e-01 | 0.1617 |
| 84866 | TMEM25 | P22T-E | Human | Esophagus | ESCC | 1.14e-14 | 2.86e-01 | 0.1236 |
| 84866 | TMEM25 | P24T-E | Human | Esophagus | ESCC | 2.17e-08 | 1.43e-01 | 0.1287 |
| 84866 | TMEM25 | P26T-E | Human | Esophagus | ESCC | 8.63e-21 | 4.25e-01 | 0.1276 |
| 84866 | TMEM25 | P27T-E | Human | Esophagus | ESCC | 1.78e-17 | 2.56e-01 | 0.1055 |
| 84866 | TMEM25 | P28T-E | Human | Esophagus | ESCC | 1.49e-10 | 1.16e-01 | 0.1149 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
| GO:0048524 | Colorectum | AD | positive regulation of viral process | 31/3918 | 65/18723 | 1.33e-06 | 4.23e-05 | 31 |
| GO:0050792 | Colorectum | AD | regulation of viral process | 59/3918 | 164/18723 | 5.95e-06 | 1.52e-04 | 59 |
| GO:0000910 | Colorectum | AD | cytokinesis | 59/3918 | 173/18723 | 3.74e-05 | 6.75e-04 | 59 |
| GO:0061640 | Colorectum | AD | cytoskeleton-dependent cytokinesis | 37/3918 | 100/18723 | 1.58e-04 | 2.20e-03 | 37 |
| GO:0006487 | Colorectum | AD | protein N-linked glycosylation | 25/3918 | 65/18723 | 9.12e-04 | 8.71e-03 | 25 |
| GO:0006486 | Colorectum | AD | protein glycosylation | 64/3918 | 226/18723 | 4.86e-03 | 3.27e-02 | 64 |
| GO:0043413 | Colorectum | AD | macromolecule glycosylation | 64/3918 | 226/18723 | 4.86e-03 | 3.27e-02 | 64 |
| GO:0070085 | Colorectum | AD | glycosylation | 67/3918 | 240/18723 | 5.78e-03 | 3.67e-02 | 67 |
| GO:00160321 | Colorectum | SER | viral process | 118/2897 | 415/18723 | 8.36e-12 | 1.65e-09 | 118 |
| GO:00009101 | Colorectum | SER | cytokinesis | 45/2897 | 173/18723 | 2.28e-04 | 3.93e-03 | 45 |
| GO:00507921 | Colorectum | SER | regulation of viral process | 43/2897 | 164/18723 | 2.57e-04 | 4.31e-03 | 43 |
| GO:00616401 | Colorectum | SER | cytoskeleton-dependent cytokinesis | 29/2897 | 100/18723 | 4.25e-04 | 6.25e-03 | 29 |
| GO:00485241 | Colorectum | SER | positive regulation of viral process | 21/2897 | 65/18723 | 5.39e-04 | 7.57e-03 | 21 |
| GO:00064871 | Colorectum | MSS | protein N-linked glycosylation | 23/3467 | 65/18723 | 9.47e-04 | 9.54e-03 | 23 |
| GO:004217627 | Esophagus | HGIN | regulation of protein catabolic process | 119/2587 | 391/18723 | 8.09e-18 | 2.43e-15 | 119 |
| GO:001049826 | Esophagus | HGIN | proteasomal protein catabolic process | 139/2587 | 490/18723 | 1.20e-17 | 3.41e-15 | 139 |
| GO:004586227 | Esophagus | HGIN | positive regulation of proteolysis | 107/2587 | 372/18723 | 2.61e-14 | 4.60e-12 | 107 |
| GO:190336227 | Esophagus | HGIN | regulation of cellular protein catabolic process | 81/2587 | 255/18723 | 1.16e-13 | 1.93e-11 | 81 |
| GO:003497625 | Esophagus | HGIN | response to endoplasmic reticulum stress | 81/2587 | 256/18723 | 1.47e-13 | 2.32e-11 | 81 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM25 | SNV | Missense_Mutation | novel | c.463N>A | p.Val155Met | p.V155M | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| TMEM25 | SNV | Missense_Mutation | c.1042N>A | p.Gly348Arg | p.G348R | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| TMEM25 | SNV | Missense_Mutation | rs781865560 | c.868N>T | p.Arg290Cys | p.R290C | protein_coding | tolerated(0.1) | probably_damaging(0.997) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TMEM25 | SNV | Missense_Mutation | c.307N>T | p.His103Tyr | p.H103Y | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-BG-A0LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| TMEM25 | SNV | Missense_Mutation | rs782304642 | c.1096N>T | p.Pro366Ser | p.P366S | protein_coding | benign(0.051) | TCGA-BG-A220-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TMEM25 | SNV | Missense_Mutation | rs377348449 | c.127N>T | p.Arg43Trp | p.R43W | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TMEM25 | SNV | Missense_Mutation | novel | c.1075N>A | p.His359Asn | p.H359N | protein_coding | benign(0.011) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| TMEM25 | SNV | Missense_Mutation | novel | c.118N>T | p.Arg40Trp | p.R40W | protein_coding | tolerated(0.19) | benign(0.058) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response | |
| TMEM25 | SNV | Missense_Mutation | novel | c.463N>A | p.Val155Met | p.V155M | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-EY-A1GK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM25 | SNV | Missense_Mutation | rs140899282 | c.656N>T | p.Ala219Val | p.A219V | protein_coding | deleterious(0) | possibly_damaging(0.526) | TCGA-EY-A1H0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |